Clinical trial
Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex
NCT00298922 · Unity Health Toronto, Other · Unknown status
Key facts
| NCT number | NCT00298922 |
|---|---|
| Title | Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex |
| Official title | Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia Complex |
| Lead sponsor | Unity Health Toronto, Other |
| Collaborators | Cystic Fibrosis Foundation Pfizer Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Azithromycin, Placebo |
| Enrollment | 45 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Mar 3, 2006 |
| Last update posted | Jul 31, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: